EJS ACT-PD Trial Team
EJS ACT-PD trial reaches major milestone as third treatment arm opens
We’re pleased to announce that we have now opened our third treatment arm, testing Ursodeoxycholic acid (UDCA) as a potential disease-modifying treatment for Parkinson’s!
This marks a major milestone for the trial and another important step forward in our mission to find treatments that could slow or stop Parkinson’s progression!
If you’d like to learn more about UDCA, visit our website for updated FAQs: UDCA Questions and Answers
To read the full article visit the InCTU page: Parkinson’s trial EJS ACT-PD adds a new treatment arm | UCL Innovative Clinical Trials Unit
Join the EJS ACT-PD Trial
If you are interested in participating in the EJS ACT-PD trial, you will need to first complete the Registration of Interest.
Visit our Registration of Interest Page for more information and to find the link to the Registration Form.